Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens

AIM: There is a critical need for effective therapies that are immediately available to control the spread of COVID-19 disease. MATERIAL & METHODS: Gamunex(®)-C and Flebogamma(®) DIF (Grifols) intravenous immunoglobulin (IVIG) products were tested using ELISA techniques for antibodies against se...

Descripción completa

Detalles Bibliográficos
Autores principales: Díez, José-María, Romero, Carolina, Gajardo, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222542/
https://www.ncbi.nlm.nih.gov/pubmed/32397847
http://dx.doi.org/10.2217/imt-2020-0095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222542/
https://www.ncbi.nlm.nih.gov/pubmed/32397847
http://dx.doi.org/10.2217/imt-2020-0095

Ejemplares similares